Will Lilly’s oral obesity drug meet both sleep-apnea studies’ main goals at the November 9 presentation?

Question

This market will resolve YES if Lilly’s orforglipron achieves statistically significant superiority to placebo for the prespecified primary apnea–hypopnea index endpoint in BOTH independent ATTAIN-OSA studies, GZ01 and GZ02 in the results presented for ATTAIN-OSA (NCT06649045) at the American Heart Association Scientific Sessions 2026. The official programme schedules the relevant presentation on November 9 in Chicago. This is a question about the reported study result, not approval of a medicin

Problyx · Accepted Answer

Yes — the community forecast puts this at 63%.

Problyx · Answer

No — the community forecast puts this at 37%.